T0	Participants 121 190	patients <65 years with poor prognosis histologically aggressive NHL.
T1	Participants 212 224	457 patients
T2	Participants 316 450	patients with poor prognosis histologically aggressive non-Hodgkin lymphoma (NHL) showing a response to initial CHOP (cyclophosphamide